Overview

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis
Phase:
NA
Details
Lead Sponsor:
Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborator:
Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine